➤ Topline results from Phase 3 studies for nAMD treatment ➤ Phase 2 trial of betamethasone treatment for cataract surgery pain and inflammation ➤ Fast Track designation given to therapy seeking to treat achromatopsia ➤ Topline data from Phase 1 trial of travoprost intracameral implant ➤ ASCRS Journal Club
➤ Enrollment complete for Phase 3 studies of investigational dry eye drug ➤ Update from two Glaukos trials ➤ Study: Remote monitoring with implantable IOP sensor affects clinical decision making ➤ ASCRS events
➤ Commercial launch of Alcon’s Vivity IOL ➤ Topline results from Phase 2 trial for treatment of contact lens discomfort ➤ Company registers new artificial intelligence visual field exam device with FDA ➤ Positive Phase 3 results for faricimab for DME ➤ Research begins to create a MIGS patient-reported outcomes instrument ➤ ASCRS events
As I write this, we are in the ninth month of the COVID pandemic, and each day brings a record number of new cases in the third wave of the virus. As a glaucoma specialist in New York City, my practice has surely seen some ups and downs over the past year. We have had to adapt tremendously, and perhaps now is a good time to reflect on some of these changes.
Where do drops fit in the era of interventional glaucoma—a time when there are new technologies, new drug delivery systems, and several MIGS options?
Depending on what you define as a microinvasive glaucoma surgery (MIGS), you might think it first became available several decades ago with endocyclophotocoagulation (ECP), but many define the MIGS era beginning with the iStent (Glaukos), the first ab interno trabecular microbypass device approved by the FDA in 2012.
Many ophthalmologists have fielded questions about marijuana use and eye health, particularly if they are in a state where medical marijuana is legal.
Is an angle closure glaucoma suspect off the hook once the laser peripheral iridotomy (LPI) is performed? Not quite.
Over the past 2 decades, numerous epidemiologic studies have revealed that normal tension glaucoma (NTG) represents a much higher proportion of all open-angle glaucoma than previously thought. These studies have also demonstrated significant regional variation in the prevalence of NTG. This was the focus of one of the glaucoma sessions at the 2016 World Ophthalmology Congress (WOC) in Guadalajara, Mexico.
How we sleep can raise or lower IOP.